Researchers at Kobe University discovered an entirely new and unexpected mechanism by which the immune system can get rid of cells lacking molecules that identify them as part of the self in mice.
FDA’s Peter Marks says some secondary cancer cases after CAR-T therapy may be ‘causal,’ but benefits still outweigh risks: #JPM24
The FDA believes that the benefit of CAR-T therapies continues to outweigh their risks amid an ongoing investigation on cases of second blood cancers developing
January 9, 2024